ResultsIQ

ResultsIQ › Latest results › Zydus Wellness Limited

Zydus Wellness Limited strategy deck summary

NSE: ZYDUSWELL · BSE: 531335

Strategy deck of 18 Mar 2026, summarised by AI from the filing.

Q3 FY26 Net Sales ₹9,633 mn (+113.7% YoY) and EBITDA ₹610 mn (+312.2% YoY), but PAT negative at ₹(399) mn.

Key takeaways

  1. Q3 FY26 results Net Sales ₹9,633 mn (Q3 FY25: ₹4,508 mn, +113.7%); EBITDA ₹610 mn (Q3 FY25: ₹148 mn, +312.2%); PAT ₹(399) mn (Q3 FY25: ₹64 mn, -723.4%).
  2. Guidance No forward-looking guidance was provided in the presentation.
  3. Acquisition impact Comfort Click acquisition funded through a low-cost bridge loan (~5%), with interest in finance costs (~₹371 mn for Q3 FY26).
  4. Growth driver Ritebite Maxprotien business continues to significantly outperform internal projections with strong volume and value growth.
  5. Risk Q3 FY26 PBT and PAT were negative, with PAT margin at -4.1%.

Original filing on BSE

Zydus Wellness Limited Q1 FY27 results

As filed: Revenue ₹1,437 cr (+67% year on year), EBITDA ₹242 cr (+55% year on year), PAT ₹119 cr (−7% year on year), EBITDA margin 16.8% (−130 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,485 cr (+63% year on year), EBITDA ₹270 cr (+43% year on year), PAT ₹162 cr (−6% year on year), EBITDA margin 18.2% (−251 bps). Score 58 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 251 bps year on year. Tax rate 9%. Consolidated profit -6% but standalone +166%. Revenue rose ₹572 cr on a year ago, more than the ₹130 cr it added the year before. Share price after the results: +0.8% in 30 days (Nifty 500: +2.6%).
  • Q3 FY26: Revenue ₹965 cr (+109% year on year), EBITDA ₹61.0 cr (+300% year on year), PAT −₹39.9 cr (−300% year on year), EBITDA margin 6.3% (+329 bps). Score 20 of 100, Below trend. Revenue and EBITDA growth were well above the company's own trend; profit before exceptional items growth was well below it. EBITDA margin rose 329 bps year on year. Consolidated profit -765% but standalone +1%. Share price after the results: −12.0% in 30 days (Nifty 500: −0.6%).
  • Q2 FY26: Revenue ₹651 cr (+32% year on year), EBITDA ₹23.0 cr (+15% year on year), PAT −₹53.0 cr (−194% year on year), EBITDA margin 3.5% (−52 bps). Score 20 of 100, Below trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit before exceptional items growth was well below it. EBITDA margin fell 52 bps year on year. Consolidated profit -352% but standalone +0%. Revenue fell 24% from last quarter. Share price after the results: −11.5% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹861 cr (+2% year on year), EBITDA ₹156 cr (0% year on year), PAT ₹128 cr (−14% year on year), EBITDA margin 18.1% (−43 bps). Score 28 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin fell 43 bps year on year. Tax rate 12%. Consolidated profit -14% but standalone +17%. Revenue fell 6% from last quarter. Share price after the results: +0.3% in 30 days (Nifty 500: −2.4%).
  • Q4 FY25: Revenue ₹913 cr (+17% year on year), EBITDA ₹189 cr (+17% year on year), PAT ₹172 cr (+15% year on year), EBITDA margin 20.7% (+1 bps). Score 61 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was in line with it. EBITDA margin was flat year on year. Tax rate 1%. Consolidated profit +15% but standalone -29%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +7.2% in 30 days (Nifty 500: +2.4%).
  • Q3 FY25: Revenue ₹462 cr (+15% year on year), EBITDA ₹14.0 cr (+8% year on year), PAT ₹6.0 cr, EBITDA margin 3.0% (−20 bps). Score 46 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 20 bps year on year. Other income 40% of PBT. Tax rate 40%. Revenue fell 6% from last quarter.
  • Q2 FY25: Revenue ₹493 cr (+12% year on year), EBITDA ₹20.0 cr (+11% year on year), PAT ₹21.0 cr (+100% year on year), EBITDA margin 4.1% (−3 bps). Score 55 of 100, In line with trend. EBITDA margin was flat year on year. Tax rate 13%. Consolidated profit +250% but standalone +0%. Not enough history for a trend yet: scored on growth alone. Revenue fell 41% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Zydus Wellness Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.